New Delhi, April 15 -- One in six people globally are already affected by metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), and the burden is set to worsen, according to a study recently published in The Lancet Gastroenterology & Hepatology. Drawing on Global Burden of Disease 2023 data, the study estimates that 1.3 billion people were living with MASLD in 2023, a number projected to rise to 1.8 billion by 2050. The increase is driven by rising obesity, type 2 diabetes, and sedentary lifestyles across regions, including in younger populations. The analysis finds that while age-standardised severity and mortality rates have remained relatively stable over time, the ...